Circulation. 1994;90:2056 69. 799. Prasad A, Husain S, Quyyumi AA. Abnormal flow-mediated epicardial vasomotion in human coronary arteries is improved by angiotensin- converting enzyme inhibition: a potential role of bradykinin. J Am Coll Cardiol. 1999;33:796 804. 800. Tummala PE, Chen XL, Sundell CL, et al. Angiotensin II induces vascular cell adhesion molecule-1 expression in rat vasculature: A potential link between the renin-angiotensin system and atherosclero- sis. Circulation. 1999;100:1223 9. 801. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992;327: 669 77. 802. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet. 2000;355:253 9. 803. Rouleau JL, Warnica WJ, Baillot R, et al. Effects of angioten- sinconverting enzyme inhibition in low-risk patients early after coronary artery bypass surgery. Circulation. 2008;117:24 31. 804. Turnbull F, Neal B, Pfeffer M, et al. Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. J Hypertens. 2007;25:951 8. 805. Okin PM, Devereux RB, Jern S, et al. Regression of electrocardio- graphic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study. Circulation. 2003;108:684 90. 806. H5N1 avian influenza: first steps towards development of a human vaccine. Wkly Epidemiol Rec. 2005;80:277 8. 807. Davis MM, Taubert K, Benin AL, et al. Influenza vaccination as secondary prevention for cardiovascular disease: a science advisory from the American Heart Association/American College of Car- diology. J Am Coll Cardiol. 2006;48:1498 502. 808. de Diego C, Vila-Corcoles A, Ochoa O, et al. 